clinical trial · NCT07124221
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets
Changchun GeneScience Pharmaceutical Co., Ltd.·phase3·recruiting·n = 382
HyperprolactinemiaCabergoline tabletsBromocriptine mesylate tablets
brief summary
A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia
started
Sep 12, 2025
primary completion
Nov 21, 2026
completion
Dec 30, 2026
last updated
Oct 2, 2025
detailed description
A randomized, double-blind, double-dummy, active controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of Cabergoline tablets compared with Bromocriptine mesylate tablets in female patients with hyperprolactinemia
official title
A Randomized, Double-blind, Double-dummy, Positive Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Female Patients With Hyperprolactinemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol